ScholarIQanswers from OpenAlex & ORCID
Thomas Holst‐Hansen
ResearcherPublications, citations & collaboration network
Thomas Holst‐Hansen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Thomas Holst‐Hansen have?
ScholarIQindexed works
Thomas Holst‐Hansen has 22 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Thomas Holst‐Hansen have?
ScholarIQcitation count
Thomas Holst‐Hansen has 502 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Thomas Holst‐Hansen?
ScholarIQh-index
Thomas Holst‐Hansen has an h-index of 6 in OpenAlex.
What is the i10-index of Thomas Holst‐Hansen?
ScholarIQi10-index
Thomas Holst‐Hansen has an i10-index of 5 in OpenAlex.
What is the ORCID of Thomas Holst‐Hansen?
ScholarIQorcid
The ORCID for Thomas Holst‐Hansen is on the source record.
What is the OpenAlex record for Thomas Holst‐Hansen?
ScholarIQopenalex
The OpenAlex for Thomas Holst‐Hansen is on the source record.
What are the most-cited papers on Thomas Holst‐Hansen?
ScholarIQmost cited works
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Filip K. Knop, Vanita R. Aroda, Ruben D do Vale, Thomas Holst‐Hansen, Peter Nørkjær Laursen, Julio Rosenstock, Domenica Rubino, W. Timothy Garvey
Spatiotemporal NF-κB dynamics encodes the position, amplitude, and duration of local immune inputs
Minjun Son, Tino Frank, Thomas Holst‐Hansen, Andrew G. Wang, Michael Junkin, Sara Saheb Kashaf, Ala Trusina, Savaş Tay
Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity
Lua Wilkinson, Thomas Holst‐Hansen, Peter Nørkjær Laursen, Anders R. Rinnov, Rachel L. Batterham, W. Timothy Garvey
The association between body mass index and health‐related quality of life in the 2017 and 2018 health survey of England data: A cross‐sectional observational analysis
Xiao Wen Luah, Thomas Holst‐Hansen, Christopher Lübker
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial
Filip K. Knop, George Kunos, Dror Dicker, Jean‐Sébastien Paquette, Louis J. Aronne, Ofir Frenkel, Thomas Holst‐Hansen, Karine Lalonde, Jisoo Lee, Glenn Crater